ATXS stock icon

Astria Therapeutics
ATXS

$11.46
1.87%
 

About: Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Employees: 59

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 10 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

485% more call options, than puts

Call options by funds: $51M | Put options by funds: $8.72M

187% more capital invested

Capital invested by funds: $283M [Q4 2023] → $811M (+$528M) [Q1 2024]

167% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 12

52% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 25

50% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 3 (+1) [Q1 2024]

25% more funds holding

Funds holding: 80 [Q4 2023] → 100 (+20) [Q1 2024]

3.44% more ownership

Funds ownership: 101.54% [Q4 2023] → 104.97% (+3.44%) [Q1 2024]

Research analyst outlook

10 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$16
40%
upside
Avg. target
$19.30
68%
upside
High target
$27
136%
upside

10 analyst ratings

10 positive
100%
neutral
0%
negative
0%
Oppenheimer
Hartaj Singh
118%upside
$25
Outperform
Maintained
21 May 2024
HC Wainwright & Co.
Joseph Pantginis
40%upside
$16
Buy
Reiterated
10 May 2024
Wedbush
Laura Chico
92%upside
$22
Outperform
Reiterated
10 May 2024
HC Wainwright & Co.
Joseph Pantginis
40%upside
$16
Buy
Maintained
23 Apr 2024
Wedbush
Laura Chico
48%upside
$17
Outperform
Maintained
26 Mar 2024

Financial journalist opinion